18 June 2021

COVID-19 vaccine safety update

COVID-19 VACCINE JANSSEN
Janssen-Cilag International NV

There are no updates to the product information.
COVID-19 Vaccine Janssen is effective in preventing COVID-19.

This safety update follows the last update of 11 May 2021.

Safety updates provide information about the assessments of emerging worldwide safety data since marketing authorisation for COVID-19 vaccines. Safety assessments are carried out primarily by EMA’s Pharmacovigilance Risk Assessment Committee (PRAC). The safety updates are published regularly at COVID-19 vaccines: authorised.

All published safety updates for COVID-19 Vaccine Janssen are available at COVID-19 Vaccine Janssen: safety updates.
Since its marketing authorisation in the European Union (EU) on 11 March 2021 until 10 June 2021, almost 5 million doses of COVID-19 Vaccine Janssen have been administered in the EU/EEA¹.

1. Updates on safety of COVID-19 Vaccine Janssen

Based on new safety data including the latest Monthly Summary Safety Report (MSSR)² from the marketing authorisation holder and data reported by patients and healthcare professionals to EudraVigilance (see section 3), PRAC assessed the following at its meeting held 7 to 10 June 2021:

Myocarditis and pericarditis

PRAC is continuing its assessment of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane around the heart) reported in a small number of people following vaccination with COVID-19 vaccines. This assessment follows case reports of myocarditis/pericarditis after vaccination with Comirnaty, another COVID-19 vaccine, as presented in the Comirnaty safety update of May 2021³.

For COVID-19 Vaccine Janssen, only one case of pericarditis had been reported from the EU/EEA to EudraVigilance by the end of May 2021, at which time around 2 million doses of COVID-19 Vaccine Janssen had been administered in the EU/EEA. Cases reported to EudraVigilance concern suspected side effects, i.e. medical events that have been observed after vaccination, but which are not necessarily related to or caused by the vaccine.

Currently, further analysis is needed to conclude whether there is a causal relationship between myocarditis/pericarditis and COVID-19 vaccines, and PRAC has requested additional data from the companies marketing the vaccines.

PRAC encourages all healthcare professionals and patients to report any cases of myocarditis or pericarditis and other adverse events occurring in people after vaccination.

Myocarditis and pericarditis are inflammatory diseases of the heart that can occur following infections or immune diseases. Depending on the data source, the incidence estimates for myocarditis and pericarditis in the

¹ The European Centre for Disease Prevention and Control (ECDC) collects these data from EU Member States as well as from the additional countries of the European Economic Area (EEA) Norway, Iceland and Liechtenstein.
² Monthly Summary Safety Reports, also referred to as pandemic summary safety reports, will be compiled by the marketing authorisation holders to support timely and continuous benefit-risk evaluations for COVID-19 vaccines used during the pandemic. These reports complement the submission of Periodic Safety Update Reports (PSURs).
general (unvaccinated) EU/EEA population prior to the COVID-19 pandemic range from 1 to 10 in 100,000 people per year. Symptoms of myocarditis and pericarditis can vary but often include shortness of breath, a forceful heartbeat that may be irregular and chest pain. The conditions usually improve on their own or with treatment. Patients who have such symptoms should consult their doctor⁴.

Embolic and thrombotic events with a focus on thrombosis with thrombocytopenia syndrome (TTS)

In April and May 2021, the product information of COVID-19 Vaccine Janssen was updated with regard to the very rare risk of thrombosis (formation of blood clots in the blood vessels) with thrombocytopenia (low blood platelets) syndrome (TTS)⁵. In June 2021, PRAC considered the current data consistent with the aspects known so far for TTS.

TTS requires rapid identification and urgent clinical management. On 7 June 2021, EMA issued a communication to raise awareness of clinical care recommendations to manage suspected TTS. The recommendations from the International Society on Thrombosis and Haemostasis (ISTH)⁶ and learned societies in EU Member States were specifically highlighted⁷. PRAC will continue to closely monitor TTS.

2. Other information for COVID-19 Vaccine Janssen

COVID-19 Vaccine Janssen is a vaccine that was authorised in the EU on 11 March 2021 for use in people aged 18 years and older to prevent COVID-19 when infected with the coronavirus SARS-CoV-2. COVID-19 is a potentially severe disease that may result in death.

COVID-19 Vaccine Janssen contains an adenovirus that has been modified to carry molecules of DNA, which the body uses to temporarily produce the SARS-CoV-2 spike protein. The spike protein does not cause COVID-19. The adenovirus cannot reproduce and does not cause viral disease.

Before COVID-19 Vaccine Janssen was granted an EU marketing authorisation, the efficacy and safety of the vaccine were assessed through pre-clinical studies and large clinical trials. More than 27,000 participants have been given the vaccine in clinical trials.

---

⁶ See [International Society of Thrombosis and Haemostasis](https://www.isth.org/)
Like all medicines, this vaccine can cause side effects, although not everybody will experience them. The most common side effects known for COVID-19 Vaccine Janssen are usually mild or moderate and get better within a few days after vaccination.

More information on how COVID-19 Vaccine Janssen works and its use is available in all EU/EEA languages in the medicine overview. This includes information on use in pregnant and breastfeeding women and immunocompromised individuals.

The full product information with the summary of product characteristics and the package leaflet is also available in all EU/EEA languages.

3. How safety is monitored

As for all COVID-19 vaccines, relevant new information emerging on COVID-19 Vaccine Janssen is collected and promptly reviewed. This is in line with the pharmacovigilance plan for COVID-19 vaccines of the EU regulatory network (comprising the regulatory bodies of the EU Member States, EMA and the European Commission).

Collecting case reports of suspected side effects

The EU regulatory network continuously monitors reports of suspected side effects observed in vaccinated individuals. These case reports are collected and recorded in EudraVigilance, a system operated by EMA for managing and analysing information on suspected side effects of medicines.

Vaccinated individuals and healthcare professionals should report suspected side effects via the national reporting systems, which also contribute to EudraVigilance. For more information, see Reporting suspected side effects. Information on how to report in your Member State is available in the package leaflet and via the list of national competent authorities.

You may visit EudraVigilance – European database of suspected drug reaction reports in all EU/EEA languages and search for “COVID-19 VACCINE JANSSEN (AD26.COV2.S)” to see all suspected side effects reported for COVID-19 Vaccine Janssen in the EU/EEA. Please note that these reports describe suspected side effects in individuals, i.e. these events may not necessarily have been caused by, or be otherwise related to, the vaccine.

Planned and ongoing studies

The company that markets COVID-19 Vaccine Janssen will continue to provide results from ongoing clinical trials. It will also conduct additional studies to monitor the safety and effectiveness of the vaccine as it is used in vaccination campaigns and other clinical practice. For the list of planned
and ongoing safety studies for COVID-19 Vaccine Janssen, see the risk management plan.

A paediatric investigation plan (PIP) for COVID-19 Vaccine Janssen is in place. This describes how the company will collect data on the vaccine’s efficacy and safety for its potential use in children.

In addition, EMA is coordinating observational studies in EU Member States looking at real-world data from clinical practice to monitor the safety and effectiveness of COVID-19 vaccines, including in pregnant women.